Global Dementia Legacy Event: Canada & France: Dr Etienne Hirsch & Dr Yves Joanette CIHR

1,491 views

Published on

Session Five: The next goal – towards Canada, France, Japan and the United States.

Canada & France: Dr Etienne Hirsch, Director, Institute for Neurosciences, Cognitive sciences, Neurology and Psychiatry at INSERM and the French alliance for life and health science Aviesan & Dr Yves Joanette CIHR, Scientific Director, Canadian Institutes of Health Research (CIHR), Institute of Aging & World Dementia Council Member

Published in: Health & Medicine, Business
  • Be the first to like this

Global Dementia Legacy Event: Canada & France: Dr Etienne Hirsch & Dr Yves Joanette CIHR

  1. 1. Canada-France Legacy Event on Dementia Prof. Yves Joanette Scientific Director, CIHR Institute of Aging Executive Director, CIHR International Collaborative Research Strategy for Alzheimer's Disease Dr. Etienne Hirsch Director multi-agency thematic institute (ITMO), neurosciences, cognitive sciences, neurology and psychiatry,
  2. 2. 2 Canada-France Legacy Event on Dementia Harnessing the Power of Discoveries: Maximizing Academia and Industry Synergies September 11–12, 2014 Ottawa, Canada Co-organized by:
  3. 3. 3  Canada and France have a strong history of working collaboratively in the area of dementia research  Canada and France have both developed collaborative models involving academic and industrial partners in this sector (French Alzheimer Plan, Canadian Consortium on Neurodegeneration in Aging)  Canada and France both have a track record of engaging in national and international research consortia on dementia (e.g. the France- chaired EU Joint Programme – Neurodegenerative Diseases; Canada’s International Collaborative Research Strategy on Alzheimer’s Disease) Why Canada and France as Co-leads?
  4. 4. 4 Bringing Research Discoveries to Life The Canada-France Legacy Event aims to develop an action framework to address current challenges and barriers for enhanced collaboration between researchers and industry. developing new diagnostic and therapeutic approaches facing the new pharmaceutical research environment engaging medical devices, biotechnology and IT industries taking full advantage of open innovation and big data
  5. 5. 5 Participants 40% academia 40% industry 20% policy makers / funders / regulatory organizations / patient organizations Approximately 180 participants from G7 countries and other organizations:
  6. 6. 6 Program Overview Day 1 Official Introductions Session 1 – Setting the Stage • An appeal for action from an individual with dementia • Achieving an innovative Academia-Industry synergy - The real life example • An arms-length view of the conditions for success to enhance synergy between academia and industry Session 2 – The Biotech and Venture Capital Challenge • When Biotech companies take advantage of the Academia/Industry Synergy – A real life example • An example of a Biotech Hub – Fostering synergies between academia and industry • Conditions of Success for Biotech Hub: A comparison of different jurisdictions
  7. 7. 7 Program Overview Session 3 – The Pharmaceutical Sector - The New Paradigm • Conditions of Success for Biotech Hub: A comparison of different jurisdictions • Bringing Academia and Pharmaceutical together in the European Space – The Innovative Medicines Initiative • Addressing the barriers for Innovative pharmaceutical Solution for Dementia Session 4 – The New Opportunities from the Medical Device and IT Industry • The role of Academia for SMEs in Developing Tele-Medicine Solution for Dementia – A real life example • How can Established Information Technology Industry benefit from enhanced synergy with Academia • Putting academia and Industry Together in Europe for Dementia – The Ambient Assisted Living Initiative • How to ensure that e-Health and Tele-Medicine solutions for dementia will support health systems
  8. 8. 8 Program Overview Day 2 Session 5 – Solutions to Barriers – Part I • The Regulatory Solutions Discussed at the Alzheimer's Disease Summit - The Path to 2025, New York Academy of Sciences • Solutions to the Regulatory Barriers – The Point of View of Regulatory Bodies Session 6 – Solutions to Barriers – Part II • Status Report on the Big Data and Sustainability Initiative for large scale research on Dementia • The Role of Open Innovation to foster Academia/Industry Solutions for Dementia • Societal Acceptability of Innovative Research approach between Academia and Industry - Results of the Canada/France Survey
  9. 9. 9 Contribution to the Priorities of the World Dementia Council The Canada-France Legacy Event will focus primarily on the three following priorities: • Finance • Research collaboration • Regulation and trials • Sharing knowledge • Health and care • Awareness
  10. 10. 10 Canada-France Legacy Event on Dementia Harnessing the Power of Discoveries: Maximizing Academia and Industry Synergies September 11–12, 2014 Ottawa, Canada Co-organized by:

×